# Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

> **NCT06168851** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 60 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** Anti-CD38 antibody Injection

## Key facts

- **NCT ID:** NCT06168851
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2025-12
- **Final completion:** 2030-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168851, "Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT06168851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*